High-performance biopolymers will soon be available for use
at industrial scale, contributing to a more circular economy with
new renewable materials
WILMINGTON, Del., Dec. 19,
2023 /PRNewswire/ -- IFF (NYSE:IFF) and Kemira today
announced their next step in the collaboration to commercialize a
portfolio of unique, renewable polymers derived from IFF's
cutting-edge Designed Enzymatic Biomaterials (DEB) technology
platform. These unique, renewable polymers derived from plant
sugars will be available for the first time at industrial scale to
supply a range of markets. This new market development
biomanufacturing facility will be integrated into Chemigate Ltd's
biorefinery, a member of the Berner Group in Finland, and will be operational in
mid-2024.
The IFF-Kemira collaboration addresses Kemira's growing demand
for alternatives to traditional fossil-based synthetic polymers
across pulp, paper, and paper-based packaging markets and in
industrial and municipal water treatment sectors. This follows
Kemira's advances in application development programs, particularly
in strength, dewatering, and barrier applications.
IFF's DEB technology was launched earlier in 2023 for use in
home and personal care markets. By expanding the application and
commercialization of its DEB technology, IFF's customers will now
have access to the new product lines of high-performance material
solutions that promote a circular bioeconomy at a sufficient scale
for industrial use. This will enable IFF to commercially supply
lead customers and support strategic application development
programs at scale. These materials expand IFF's AURIST™ biopolymers
for personal care applications, and IFF's Nuvolve® engineered
polysaccharides for industrial applications.
"In today's world, innovation must go hand-in-hand with
sustainability," said Christian
Lenges, IFF venture director. "It is a topic of conversation
at nearly every customer meeting. For years, 'green' products were
deemed inferior in performance to fossil-based alternatives, but
this is no longer the case. We are proud to leverage our bioscience
knowledge to develop the DEB technology platform, allowing us to
provide the first commercial quantities for our partners and
customers."
"This is a major step in our growth strategy implementation and
our journey to build a leading renewable materials portfolio," said
Sampo Lahtinen, SVP growth
accelerator, Kemira Oyj. "This cutting-edge biotechnology platform
enables the production of renewable polymers, which combine high
performance with significant improvements in the sustainability
profile, including end-of-life properties such as recyclability and
biodegradability. We are excited to scale up new alternatives to
fossil-based products without compromising performance and
competitiveness."
"We're pleased to support IFF and Kemira with material
biomanufacturing integrated at our biorefinery at Finnamyl, with
the aim of driving positive change across a range of industries,"
said Tom Schauman, CEO, Chemigate.
"Manufacturers will now have access to commercially relevant
quantities of IFF's Designed Enzymatic Biomaterials, to improve
sustainability across a series of market segments."
To learn more about how the DEB technology platform is powering
a new frontier in biomaterial innovation, visit here.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage,
health, biosciences and scent, science and creativity meet to
create essential solutions for a better world – from global icons
to unexpected innovations and experiences. With the beauty of art
and the precision of science, we are an international collective of
thinkers who partners with customers to bring scents, tastes,
experiences, ingredients and solutions for products the world
craves. Together, we will do more good for people and planet. Learn
more at iff.com, X
(Twitter) , Facebook, Instagram,
and LinkedIn.
©2023 International Flavors & Fragrances Inc. (IFF). IFF,
the IFF Logo, and all trademarks and service marks denoted with
TM, SM or ® are owned by IFF or affiliates of
IFF unless otherwise noted. All Rights Reserved.
Contact:
Brenda Heffelfinger
VP of Marketing and Commercial Excellence, Health &
Biosciences
+1 609 504 9979
brenda.heffelfinger@iff.com
SOURCE IFF